Peterson Andrew M, Bockover Spencer R, Kallogjeri Dorina, Chang Katherine, Tharakan Theresa, Harbison R Alex, Zolkind Paul, Rich Jason T, Pipkorn Patrik, Puram Sidharth V, Jackson Ryan S
Head and Neck Tumor Center at Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.
Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri.
JAMA Otolaryngol Head Neck Surg. 2025 Jul 10. doi: 10.1001/jamaoto.2025.1833.
The palatine tonsil is the most common subsite of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (SCC). There is debate on how to manage the contralateral clinically uninvolved tonsil in patients undergoing a primary surgical approach via transoral robotic surgery (TORS).
To assess postoperative complications, functional outcomes, contralateral tonsil second primary rates, and survival in patients undergoing unilateral vs bilateral TORS with pathology-guided adjuvant treatment.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was carried out in a quaternary care academic medical center. All consecutive unilateral tonsillar patients with SCC undergoing TORS as primary treatment from June 2016 to July 2023 were included. Analysis was conducted between October 1, 2024, and January 1, 2025.
Unilateral TORS (ipsilateral radical tonsillectomy) vs bilateral TORS (ipsilateral radical tonsillectomy and contralateral extracapsular tonsillectomy).
The primary outcome measure was rate of postoperative oropharyngeal hemorrhage. Secondary outcome measures included postoperative emergency department (ED) visit/hospitalization rate, time to nasogastric tube (NGT) removal, rate of discharge with an NGT tube, G-tube dependence rates, second primary rates in the contralateral tonsil, length of stay, and 2-year and 5-year disease-free survival (DFS) and overall survival (OS).
A total of 158 (106 unilateral, 52 bilateral TORS) patients with HPV-associated tonsillar SCC were evaluated, including 18 women and 139 men with a mean (SD) age of 60 (10) years. There were clinically meaningful differences in oropharyngeal hemorrhage rates (7% vs 15%; percent difference, -7.8; 95% CI, -18.8% to 3.2%), 30-day ED visit/hospitalization rates (9% vs 21%; percent difference, -11.7%; 95% CI, -24.1 to 0.7), and median length of stay (2 vs 3 days) for unilateral and bilateral TORS, respectively. Swallowing outcomes, DFS, and OS were not significantly different between the 2 groups. A total of 3 patients (1.9%) had a second primary tumor in the contralateral tonsil, including 2 metachronous primary tumors in the unilateral group (1.8%) and 1 synchronous primary tumor incidentally removed at the time of surgery in the bilateral group (1.9%).
This cohort study found that omission of contralateral elective extracapsular tonsillectomy in HPV-positive SCC was safe and associated with a trend toward lower posttonsillectomy hemorrhage, postoperative ED visits for pain control, and hospital length of stay without compromising survival. Prophylactically resecting the contralateral tonsil may add patient harm without any clear benefits.
腭扁桃体是人类乳头瘤病毒(HPV)相关口咽鳞状细胞癌(SCC)最常见的亚部位。对于接受经口机器人手术(TORS)进行初次手术的患者,如何处理对侧临床上未受累的扁桃体存在争议。
评估接受单侧与双侧TORS并接受病理引导辅助治疗的患者的术后并发症、功能结局、对侧扁桃体第二原发癌发生率及生存率。
设计、设置和参与者:在一家四级医疗学术医学中心进行了一项回顾性队列研究。纳入了2016年6月至2023年7月期间所有连续接受TORS作为主要治疗的单侧扁桃体SCC患者。分析于2024年10月1日至2025年1月1日进行。
单侧TORS(同侧根治性扁桃体切除术)与双侧TORS(同侧根治性扁桃体切除术和对侧扁桃体包膜外切除术)。
主要结局指标为术后口咽出血率。次要结局指标包括术后急诊科(ED)就诊/住院率、鼻胃管(NGT)拔除时间、带NGT管出院率、胃造口管依赖率、对侧扁桃体第二原发癌发生率、住院时间以及2年和5年无病生存率(DFS)和总生存率(OS)。
共评估了158例(单侧106例,双侧TORS 52例)HPV相关扁桃体SCC患者,包括18名女性和139名男性,平均(标准差)年龄为60(10)岁。单侧和双侧TORS的口咽出血率(7%对15%;百分比差异,-7.8;95%CI,-18.8%至3.2%)、30天ED就诊/住院率(9%对21%;百分比差异,-11.7%;95%CI,-24.1至0.7)以及中位住院时间(2天对3天)存在临床意义上的差异。两组之间的吞咽结局、DFS和OS无显著差异。共有3例患者(1.9%)对侧扁桃体出现第二原发肿瘤,包括单侧组2例异时性原发肿瘤(1.8%)和双侧组手术时偶然切除的1例同时性原发肿瘤(1.9%)。
这项队列研究发现,在HPV阳性SCC中省略对侧选择性扁桃体包膜外切除术是安全的,且与扁桃体切除术后出血率降低、术后因疼痛控制到ED就诊以及住院时间缩短的趋势相关,而不影响生存率。预防性切除对侧扁桃体可能会给患者带来伤害且无明显益处。